Nuveen
FDMT icon

Nuveen’s 4D Molecular Therapeutics FDMT Stock Holding History

Nuveen’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.69M Sell
503,071
-58,734
-10% -$572K ﹤0.01% 1938
2026
Q1 		$5.23M Buy
561,805
+403,036
+254% +$3.51M ﹤0.01% 1855
2025
Q4 		$1.19M Buy
158,769
+64,850
+69% +$658K ﹤0.01% 2539
2025
Q3 		$816K Sell
93,919
-6,786
-7% -$40.6K ﹤0.01% 2712
2025
Q2 		$374K Sell
100,705
-49,609
-33% -$174K ﹤0.01% 2970
2025
Q1 		$486K Buy
150,314
+26,846
+22% +$126K ﹤0.01% 2914
2024
Q4 		$688K Hold
123,468
– – ﹤0.01% 2868
2024
Q3 		$1.33M Hold
123,468
– – ﹤0.01% 2627
2024
Q2 		$2.59M Buy
123,468
+14,718
+14% +$369K ﹤0.01% 2258
2024
Q1 		$3.46M Hold
108,750
– – ﹤0.01% 2148
2023
Q4 		$2.2M Buy
108,750
+1,383
+1% +$18.2K ﹤0.01% 2368
2023
Q3 		$1.37M Buy
107,367
+10,047
+10% +$168K ﹤0.01% 2447
2023
Q2 		$1.76M Sell
97,320
-59,311
-38% -$1.09M ﹤0.01% 2410
2023
Q1 		$2.69M Buy
156,631
+27,534
+21% +$535K ﹤0.01% 2214
2022
Q4 		$2.87M Sell
129,097
-17,104
-12% -$264K ﹤0.01% 2222
2022
Q3 		$1.18M Sell
146,201
-314
-0.2% -$2.84K ﹤0.01% 2672
2022
Q2 		$1.02M Buy
146,515
+52,662
+56% +$512K ﹤0.01% 2768
2022
Q1 		$1.47M Sell
93,853
-3,473
-4% -$54.5K ﹤0.01% 2656
2021
Q4 		$1.93M Buy
97,326
+6,424
+7% +$157K ﹤0.01% 2576
2021
Q3 		$3.16M Buy
90,902
+63,980
+238% +$1.82M ﹤0.01% 2448
2021
Q2 		$648K Buy
26,922
+9,191
+52% +$281K ﹤0.01% 3128
2021
Q1 		$769K Buy
+17,731
New +$785K ﹤0.01% 2978

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Nuveen's FDMT Position: Q2 2026 in Review

Nuveen reduced its 4D Molecular Therapeutics (FDMT) stake by 10% in Q2 2026, selling an estimated $572K and leaving 503,071 shares worth $6.69M. The position accounts for ﹤0.01% of the portfolio, ranked #1938.

Nuveen first reported a position in FDMT in Q1 2021 and has held it in 22 quarters since. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Nuveen held 503,071 shares of 4D Molecular Therapeutics worth $6.69M as of Q2 2026.
  • Nuveen sold 58,734 4D Molecular Therapeutics shares in Q2 2026, an estimated $572K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1938 holding.
  • Nuveen first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.